Phase I and Pharmacokinetic Study of Continuous Twice Weekly Intravenous Administration of Cilengitide (EMD 121974), a Novel Inhibitor of the Integrins Αvβ3 and Αvβ5 in Patients with Advanced Solid Tumours
European Journal of Cancer（2003）
Key words
phase I clinical trial,angiogenesis inhibitor,integrins,Cilengitide (EMD 121974),pharmacology
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined